Felix Moser is the Chief Scientific Officer of Synlife, an early-stage startup based in Cambridge, MA developing novel healthcare solutions based on Synthetic Minimal Cell (SynellTM) technologies. Synthetic minimal cells, unlike extant organisms, offer the advantages of being wholly defined in their chemical makeup while still being completely programmable. In the healthcare space, SynellsTM promise a new paradigm in pharmacotherapeutics that marries targeting with in situ production of protein medicine to deliver personalized medicine at a cellular level.Felix has worked in synthetic biology since 2008 and has a PhD in Bioengineering from MIT.